Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00219310 · ClinicalTrials.gov registry record · Phase 4
RELIEF: Randomized Episodic Versus Long-Term Suppression Experience With Famciclovir
A Phase 4 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 4
- Development phase
NCT00219310 is a Phase 4 study that has completed, run by Novartis.
The verdict
NCT00219310, a Phase 4 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 4
- Development phase
Study Summary
This trial will assess whether RGH patients who have two recurrent episodes within a three month period would benefit from suppressive treatment and whether patients prefer episodic therapy or suppressive therapy for the treatment of their RGH.
Interventions
- DRUG Famciclovir
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-06 |
| Est. Completion | 2005-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00219310
The ClinicalTrials.gov registry entry for NCT00219310 describes a study currently listed as completed, categorized as Phase 4. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Famciclovir is the first listed.
NCT00219310 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00219310 about?
NCT00219310 is a clinical study titled "RELIEF: Randomized Episodic Versus Long-Term Suppression Experience With Famciclovir". This trial will assess whether RGH patients who have two recurrent episodes within a three month period would benefit from suppressive treatment and whether patients prefer episodic therapy or suppressive therapy for the treatment of their RGH.
What is the current status of trial NCT00219310?
This trial is currently completed. It is a Phase 4 study. The study started on 2003-06. Estimated completion is 2005-06.
What interventions are being tested in trial NCT00219310?
The interventions under investigation include: Famciclovir (DRUG).
Who is sponsoring clinical trial NCT00219310?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.